Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price lowered by Scotiabank from $105.00 to $80.00 in a ...

Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s stock price traded down 4% during trading on Thursday after ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating reiterated by analysts at HC Wainwright in ...

12 analysts have shared their evaluations of Sarepta Therapeutics (NASDAQ:SRPT) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a ...

NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target reduced by stock analysts at Deutsche Bank ...

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 24.9% in the pre-market session after the company reported ...

Cantor Fitzgerald reiterated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a ...

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Wall Street's major averages closed in the green on Friday, and the benchmark S&P 500 (SP500) snapped a four-week losing streak after U.S. President Donald Trump said there might be some "flexibility" ...

HighTower Advisors LLC decreased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 6.5% during the ...